- Home
- PHUN vs MIST Comparison
PHUN vs MIST Comparison
Compare PHUN & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- MIST
- Stock Information
- Founded
- PHUN 2009
- MIST 2003
- Country
- PHUN United States
- MIST Canada
- Employees
- PHUN N/A
- MIST N/A
- Industry
- PHUN EDP Services
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- MIST Health Care
- Exchange
- PHUN Nasdaq
- MIST Nasdaq
- Market Cap
- PHUN 89.7M
- MIST 100.3M
- IPO Year
- PHUN N/A
- MIST N/A
- Fundamental
- Price
- PHUN $5.37
- MIST $1.98
- Analyst Decision
- PHUN Strong Buy
- MIST Strong Buy
- Analyst Count
- PHUN 3
- MIST 3
- Target Price
- PHUN $13.00
- MIST $13.00
- AVG Volume (30 Days)
- PHUN 2.3M
- MIST 636.8K
- Earning Date
- PHUN 03-11-2025
- MIST 11-12-2024
- Dividend Yield
- PHUN N/A
- MIST N/A
- EPS Growth
- PHUN N/A
- MIST N/A
- EPS
- PHUN N/A
- MIST N/A
- Revenue
- PHUN $3,537,000.00
- MIST N/A
- Revenue This Year
- PHUN N/A
- MIST N/A
- Revenue Next Year
- PHUN $93.33
- MIST N/A
- P/E Ratio
- PHUN N/A
- MIST N/A
- Revenue Growth
- PHUN N/A
- MIST N/A
- 52 Week Low
- PHUN $2.85
- MIST $1.12
- 52 Week High
- PHUN $24.00
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- PHUN 51.61
- MIST 49.21
- Support Level
- PHUN $5.01
- MIST $1.92
- Resistance Level
- PHUN $6.00
- MIST $2.07
- Average True Range (ATR)
- PHUN 0.63
- MIST 0.20
- MACD
- PHUN 0.02
- MIST -0.03
- Stochastic Oscillator
- PHUN 28.12
- MIST 9.41
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).